How to buy Viridian Therapeutics stock

Viridian Therapeutics, Inc is a biotechnology business based in the US. Viridian Therapeutics shares (VRDN) are listed on the NASDAQ and all prices are listed in US Dollars. Viridian Therapeutics employs 26 staff and has a trailing 12-month revenue of around 0.00.

Viridian Therapeutics stock price (NASDAQ: VRDN)

Use our graph to track the performance of VRDN stocks over time.

Viridian Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-26.

52-week range	$7.08 - $25.67
50-day moving average	$17.49
200-day moving average	$17.89
Wall St. target price	$35.20
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Viridian Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Viridian Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Viridian Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viridian Therapeutics financials

Revenue TTM	$1.7 million
Gross profit TTM	$-26,954,000
Return on assets TTM	-39.18%
Return on equity TTM	-182.16%
Profit margin	0%
Book value	N/A
Market capitalisation	$145 million

TTM: trailing 12 months

Shorting Viridian Therapeutics shares

There are currently 80,716 Viridian Therapeutics shares held short by investors – that's known as Viridian Therapeutics's "short interest". This figure is 7.7% down from 87,454 last month.

There are a few different ways that this level of interest in shorting Viridian Therapeutics shares can be evaluated.

Viridian Therapeutics's "short interest ratio" (SIR)

Viridian Therapeutics's "short interest ratio" (SIR) is the quantity of Viridian Therapeutics shares currently shorted divided by the average quantity of Viridian Therapeutics shares traded daily (recently around 40972.588832487). Viridian Therapeutics's SIR currently stands at 1.97. In other words for every 100,000 Viridian Therapeutics shares traded daily on the market, roughly 1970 shares are currently held short.

However Viridian Therapeutics's short interest can also be evaluated against the total number of Viridian Therapeutics shares, or, against the total number of tradable Viridian Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viridian Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Viridian Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable Viridian Therapeutics shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Viridian Therapeutics.

Find out more about how you can short Viridian Therapeutics stock.

Viridian Therapeutics share dividends

We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.

Have Viridian Therapeutics's shares ever split?

Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.

Viridian Therapeutics share price volatility

Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $7.08 up to $25.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 1.2866. This would suggest that Viridian Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viridian Therapeutics overview

Viridian Therapeutics, Inc. , a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc.

Frequently asked questions

What percentage of Viridian Therapeutics is owned by insiders or institutions?
Currently 4.113% of Viridian Therapeutics shares are held by insiders and 80.494% by institutions. How many people work for Viridian Therapeutics?
Latest data suggests 26 work at Viridian Therapeutics. When does the fiscal year end for Viridian Therapeutics?
Viridian Therapeutics's fiscal year ends in December. Where is Viridian Therapeutics based?
Viridian Therapeutics's address is: 6200 Lookout Road, Boulder, CO, United States, 80301